This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Regulatory / BioAge Labs IPO Securities Lawsuit
Regulatory class action

BioAge Labs IPO Securities Lawsuit

Analysis based on 13 articles · First reported Jan 07, 2025 · Last updated Jan 25, 2025

Sentiment
-60
Attention
4
Articles
13
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market is negatively impacted by the class action lawsuit against BioAge Labs, as it highlights potential securities fraud and significant financial losses for investors. The discontinuation of the STRIDES clinical trial caused BioAge Labs' stock to fall over 76%, indicating a loss of investor confidence in its drug development pipeline.

Biotechnology Pharmaceuticals Legal Services
Event Summary

Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against BioAge Labs, alleging violations of the Securities Act of 1933. The lawsuit claims that BioAge Labs' registration statement for its September 26, 2024 IPO was materially false and misleading, specifically regarding the safety and expected results of its STRIDES clinical trial. On December 6, 2024, BioAge Labs discontinued the STRIDES Phase 2 study of its drug candidate azelaprag due to observed liver transaminitis, leading to a more than 76% drop in its stock price. Investors who purchased BioAge Labs stock in the IPO have until March 10, 2025, to seek appointment as lead plaintiff in the lawsuit.

Key Actions
98 BioAge Labs discontinued trial
95 Robbins Geller Rudman & Dowd LLP announced class action BioAge Labs
90 BioAge Labs issued registration statement
90 Levi & Korsinsky notified investors BioAge Labs
Entities Involved
priv
Robbins Geller Rudman & Dowd LLP
Robbins Geller Rudman & Dowd LLP is the law firm announcing and leading the class action lawsuit against BioAge Labs, representing investors who suffered losses.
Importance 80.0 Sentiment 50.0
per
J. C. Sanchez
J. C. Sanchez is an attorney at Robbins Geller Rudman & Dowd LLP, listed as a contact for investors interested in the BioAge Labs class action lawsuit.
Importance 30.0 Sentiment 20.0
per
Jennifer N. Caringal
Jennifer N. Caringal is an attorney at Robbins Geller Rudman & Dowd LLP, listed as a contact for investors interested in the BioAge Labs class action lawsuit.
Importance 30.0 Sentiment 20.0
priv
BioAge Labs
Importance 0.0 Sentiment 0.0
govactor
United States — United States District Court for the Northern District of California
Importance 0.0 Sentiment 0.0
priv
Levi & Korsinsky
Importance 0.0 Sentiment 0.0
per
Joseph E. Levi
Importance 0.0 Sentiment 0.0
Relationships
Robbins Geller Rudman & Dowd LLP related ↔ J. C. Sanchez
Robbins Geller Rudman & Dowd LLP related ↔ Jennifer N. Caringal
Robbins Geller Rudman & Dowd LLP related ↔ United States — United States District Court for the Northern District of California
Robbins Geller Rudman & Dowd LLP related ↔ Levi & Korsinsky
Robbins Geller Rudman & Dowd LLP related ↔ Joseph E. Levi
J. C. Sanchez colleague ↔ Jennifer N. Caringal J.C. Sanchez serves as a colleague and co-counsel alongside Jennifer N. Caringal at Robbins Geller Rudman & Dowd LLP, wh
J. C. Sanchez related ↔ United States — United States District Court for the Northern District of California
J. C. Sanchez related ↔ Levi & Korsinsky
J. C. Sanchez related ↔ Joseph E. Levi
Jennifer N. Caringal related ↔ Levi & Korsinsky
Jennifer N. Caringal related ↔ Joseph E. Levi
United States — United States District Court for the Northern District of California related ↔ Levi & Korsinsky
United States — United States District Court for the Northern District of California related ↔ Joseph E. Levi
Levi & Korsinsky related ↔ Joseph E. Levi
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.